Action of elgodipine on atherosclerosis development, cell growth, and oncogene expression in vascular smooth muscle cells

Gen Pharmacol. 1997 Mar;28(3):463-8. doi: 10.1016/s0306-3623(96)00067-5.

Abstract

1. Elgodipine (ELG) had no significant effect on aortic content of cholesterol, plasma cholesterol, or triglycerides concentrations in cholesterol-fed rabbits. However, ELG administration produced a dose-dependent and significant reduction of calcium content of the aorta. 2. In vitro studies showed that ELG was able to inhibit vascular smooth muscle proliferation through a mechanism independent of the expression of the transcription factors c-fos and c-jun.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta, Thoracic / drug effects*
  • Aorta, Thoracic / metabolism
  • Arteriosclerosis / prevention & control
  • Blood Pressure / drug effects
  • Calcium / analysis
  • Calcium Channel Blockers / pharmacology*
  • Cell Division / drug effects
  • Cells, Cultured
  • Cholesterol, Dietary / administration & dosage
  • Dihydropyridines / pharmacology*
  • Gene Expression / drug effects
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / metabolism
  • Lipoproteins / blood
  • Male
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / metabolism
  • Proto-Oncogene Proteins / biosynthesis
  • Rabbits
  • Triglycerides / blood

Substances

  • Calcium Channel Blockers
  • Cholesterol, Dietary
  • Dihydropyridines
  • Lipoproteins
  • Proto-Oncogene Proteins
  • Triglycerides
  • elgodipine
  • Calcium